DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of pindolol on the prolactin response to d-fenfluramine.

Author(s): Park SB, Cowen PJ

Affiliation(s): University Department of Psychiatry, Littlemore Hospital, Oxford, UK.

Publication date & source: 1995-04, Psychopharmacology (Berl)., 118(4):471-4.

Publication type: Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers. Pindolol pretreatment lowered baseline PRL levels but, when this effect was taken into account, did not significantly attenuate the PRL response to d-FEN. Within the limitations that attend the use of pindolol as a 5-HT1A receptor antagonist, the data suggest that although 5-HT1A receptors may play a role in the tonic release of PRL, they are not involved in the release of PRL produced by d-FEN. We propose that the PRL response to d-FEN may involve selective activation of postsynaptic 5-HT2 receptors.

Page last updated: 2007-05-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017